Results 21 to 30 of about 6,366 (244)

Mitochondria Death/Survival Signaling Pathways in Cardiotoxicity Induced by Anthracyclines and Anticancer-Targeted Therapies

Biochemistry Research International, 2012
Anthracyclines remain the cornerstone of treatment in many malignancies but these agents have a cumulative dose relationship with cardiotoxicity. Development of cardiomyopathy and congestive heart failure induced by anthracyclines are typically dose ...
David Montaigne, Christopher Hurt, Remi Neviere   +2 more
doaj   +1 more source

In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521—A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics

Molecules, 2023
Anthracycline antibiotics (ANT) are among the most widely used anticancer drugs. Unfortunately, their use is limited due to the development of drug resistance and cardiotoxicity.
Marek Jamrozik, Kamil Piska, Adam Bucki, Paulina Koczurkiewicz-Adamczyk, Michał Sapa, Benedykt Władyka, Elżbieta Pękala, Marcin Kołaczkowski   +7 more
doaj   +1 more source

Cardiac Events in Childhood Cancer Survivors Treated with Anthracyclines: The Value of Previous Myocardial Strain Measurement

Life, 2022
In echocardiographic surveillance of anthracycline-treated childhood cancer survivors (CCS), left ventricular ejection fraction (LVEF) has insufficient prognostic value for future cardiac events, whereas longitudinal strain may be more sensitive.
Milanthy Pourier, Remy Merkx, Jacqueline Loonen, Alyssa van Cleef, Chris de Korte, Louise Bellersen, Livia Kapusta, Annelies Mavinkurve-Groothuis   +7 more
doaj   +1 more source

Pharmacokinetics of Anthracyclines [PDF]

Acta Oncologica, 1989
The plasma pharmacokinetics of the two commonly used anthracyclines doxorubicin and 4'epi-doxorubicin have been studied by reversed phase liquid chromatography with photometric detection. After intravenous administration the plasma pharmacokinetics of doxorubicin and 4'epi-doxorubicin are characterized by the three compartment open model.
openaire   +2 more sources

Updates in Anthracycline-Mediated Cardiotoxicity

Frontiers in Pharmacology, 2018
Cardiotoxicity is one of the main adverse effects of chemotheraphy, affecting the completion of cancer therapies and the short- and long-term quality of life.
Canan G. Nebigil, Laurent Désaubry
doaj   +1 more source

Efficacy of Physical Exercise to Offset Anthracycline‐Induced Cardiotoxicity: A Systematic Review and Meta‐Analysis of Clinical and Preclinical Studies

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Physical exercise is an intervention that might protect against doxorubicin‐induced cardiotoxicity. In this meta‐analysis and systematic review, we aimed to estimate the effect of exercise on doxorubicin‐induced cardiotoxicity and to evaluate ...
Willeke R. Naaktgeboren, David Binyam, Martijn M. Stuiver, Neil K. Aaronson, Arco J. Teske, Wim H. van Harten, Wim G. Groen, Anne M. May   +7 more
doaj   +1 more source

The first two lines of chemotherapy for anthracycline-naive metastatic breast cancer: A comparative study of the efficacy of anthracyclines and non-anthracyclines

, 2014
For anthracycline-naive metastatic breast cancer (AN-MBC), early anthracycline treatment is a common practice. However, with the availability of newer chemotherapies, comparative studies on the efficacy of anthracyclines and non-anthracyclines as early ...
陳偉武 ;盧彥伸 ;鄭安理 ;許駿 ;黃俊升 ;張端瑩 ;林璟宏, Chen, Wei-Wu;Chang, Dwan-Ying;Huang, Shu-Min;Lin, Ching-Hung;Hsu, Chun;Lin, Ming-Hwai;Huang, Chiun-Shen;Lu, Yen-Shen;Cheng, Ann-Lii   +1 more
core   +1 more source

Exercise Cardio-Oncology: Exercise as a Potential Therapeutic Modality in the Management of Anthracycline-Induced Cardiotoxicity

Frontiers in Cardiovascular Medicine, 2022
Anthracyclines are one of the most effective chemotherapy agents and have revolutionized cancer therapy. However, anthracyclines can induce cardiac injuries through ‘multiple-hits', a series of cardiovascular insults coupled with lifestyle risk factors ...
Dong-Woo Kang, Dong-Woo Kang, Rebekah L. Wilson, Rebekah L. Wilson, Cami N. Christopher, Cami N. Christopher, Amber J. Normann, Amber J. Normann, Oscar Barnes, Jordan D. Lesansee, Gyuhwan Choi, Christina M. Dieli-Conwright, Christina M. Dieli-Conwright   +12 more
doaj   +1 more source

Altered Peripheral Blood Gene Expression in Childhood Cancer Survivors With Anthracycline‐Induced Cardiomyopathy – A COG‐ALTE03N1 Report

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Anthracycline‐induced cardiomyopathy is a leading cause of premature death in childhood cancer survivors, presenting a need to understand the underlying pathogenesis.
Purnima Singh, Disheet A. Shah, Mariam Jouni, Romina B. Cejas, David K. Crossman, Tarek Magdy, Shaowei Qiu, Xuexia Wang, Liting Zhou, Noha Sharafeldin, Lindsey Hageman, Donald E. McKenna, Saro H. Armenian, Frank M. Balis, Douglas S. Hawkins, Frank G. Keller, Melissa M. Hudson, Joseph P. Neglia, A Kim Ritchey, Jill P. Ginsberg, Wendy Landier, Ravi Bhatia, Paul W. Burridge, Smita Bhatia   +23 more
doaj   +1 more source

The nuclear membrane in multidrug resistance: microinjection of epirubicin into bladder cancer cell lines

, 2005
Objevtive: to assess whether microinjecting epirubicin into cells showing multidrug resistance (MDR, common to many cancers, including bladder cancer, with resistance to, e.g.
Birch, B.R, Hayes, C.M, Featherstone, J.F, Cooper, A.J, Speers, A.G, Lwaleed, B.A   +5 more
core   +1 more source